AIM ImmunoTech Inc. Leases Disclosure
| (11) | Leases |
The Company leases office and lab facilities and other equipment under non-cancellable operating leases with initial terms typically ranging from 1 to 5 years, expiring at various dates during 2026 through 2027, and requiring monthly payments ranging from less than $1,000 to $22,000. Certain leases include additional renewal options ranging from 1 to 5 years. AIM has classified all of its leases as operating leases.
At December 31, 2025 and December 31, 2024, the balance of the right of use assets was $378,000 and $618,000, respectively, and the corresponding operating lease liability balance was $420,000 and $634,000, respectively. Right of use assets are recorded net of accumulated amortization of $560,000 and $428,000 as of December 31, 2025 and December 31, 2024, respectively.
AIM recognized rent expense associated with these leases are follows:
| Year ended December 31, | ||||||||
| (in thousands) | ||||||||
| 2025 | 2024 | |||||||
| Lease costs: | ||||||||
| Operating lease costs | $ | 294 | $ | 304 | ||||
| Short-term and variable lease costs | 250 | 283 | ||||||
| Total lease costs | $ | 544 | $ | 587 | ||||
| Classification of lease costs: | ||||||||
| Research & development | $ | 374 | $ | 446 | ||||
| General and administrative | 170 | 141 | ||||||
| Total lease costs | $ | 544 | $ | 587 | ||||
The Company’s leases have remaining lease terms between 9 and 20 months. As of December 31, 2025, the weighted-average remaining term was 20 months. At December 31, 2024, the weighted-average remaining term was 29 months. The Company’s weighted average incremental borrowing rate for its leases was 10% at December 31, 2025, and December 31, 2024.
Future minimum payments as of December 31, 2025, are as follows:
| Year Ending December 31, (in thousands) | ||||
| 2026 | $ | 273 | ||
| 2027 | 169 | |||
| Less imputed interest | (22 | ) | ||
| Total | $ | 420 | ||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 27, 2026 | Showing above |
| 2024 | Mar 27, 2025 | |
| 2023 | Apr 1, 2024 | |
| 2022 | Mar 31, 2023 | |
| 2021 | Mar 31, 2022 | |
| 2020 | Mar 31, 2021 | |
About Leases Disclosures
Lease disclosures under ASC 842 provide a comprehensive view of a company's leased asset portfolio, including the split between operating and finance leases, discount rates used to present-value future payments, and the maturity schedule of lease obligations. This section reveals a significant source of off-balance-sheet commitments that were largely hidden before the current standard.
Key signals: the weighted-average discount rate affects the size of recorded lease liabilities — a higher rate reduces the reported obligation, so compare the chosen rate against the company's incremental borrowing rate. The operating versus finance lease mix affects both EBITDA and operating income presentation. Watch the maturity table for concentration risk: large payment cliffs in specific years may create cash flow pressure. Variable lease payments excluded from the liability measurement represent real obligations that do not appear on the balance sheet. Compare total lease costs against prior-year operating lease expense to assess the true economic burden.